Glucomannan and glucomannan plus spirulina-enriched squid-surimi added to high saturated diet affect glycemia, plasma and adipose leptin and adiponectin levels in growing fa/fa rats;Las dietas hipersaturadas que contienen surimi de calamar enriquecido con glucomanano y glucomanano/espirulina afectan a la glucemia y a los niveles plasmáticos y adiposos de leptina y adiponectina en ratas fa/fa en crecimiento

Nutricion Hospitalaria

Volumn 32, Issue 6, 2015, Pages 2718-2724

  Vázquez Velasco, Miguel ^a   González Torres, Laura ^a   Méndez, María Teresa ^a   Bastida, Sara ^a   Benedí, Juana ^a   González Muñoz, M José ^b   Sánchez Muniz, Francisco J ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Functional foods; Glucomannan; Obesity; Spirulina; Type 2 diabetes mellitus

Indexed keywords

(1-6)-ALPHA-GLUCOMANNAN; ADIPONECTIN; ADIPOQ PROTEIN, RAT; ANOREXIGENIC AGENT; GLUCOSE BLOOD LEVEL; INSULIN; LEPTIN; MANNAN;

ADIPOSE TISSUE; ANALYSIS; ANIMAL; BLOOD; CHEMISTRY; DECAPODIFORMES; DIET; DRUG EFFECTS; FUNCTIONAL FOOD; GLUCOSE BLOOD LEVEL; MALE; METABOLISM; RAT; SEA FOOD; SPIRULINA; ZUCKER RAT;

ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; APPETITE DEPRESSANTS; BLOOD GLUCOSE; DECAPODIFORMES; DIET; FUNCTIONAL FOOD; INSULIN; LEPTIN; MALE; MANNANS; RATS; RATS, ZUCKER; SEAFOOD; SPIRULINA;

EID: 84949959474     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: 10.3305/nh.2015.32.6.9936     Document Type: Article

References (41)

1. Llopiz PQ, García-Galbis MR. Control glicémico a través del ejercicio en pacientes con diabetes mellitus tipo 2: Revisión sistemática. Nutr Hosp 2015; 31: 1465-1472.
2. Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, Nichols G. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 293-301.
3. Winett RA, Davy BM, Marinik E, Savla J, Winett SG, Phillips SM, Lutes LD. Developing a new treatment paradigm for disease prevention and healthy aging. Transl Behav Med 2014; 4: 117-123.
4. Hirahatake KM, Slavin JL, Maki KC, Adams SH. Associations between dairy foods, diabetes, and metabolic health: potential mechanisms and future directions. Metabolism 2014; 63: 618-627.
5. Cho SS, Qi L, Fahey GC, Klurfeld DM. Consumption of cereal fiber, mixtures of whole grains and bran, and whole grains and risk reduction in type 2 diabetes, obesity, and cardiovascular disease. Am J Clin Nutr 2013; 98: 594-619.
6. Borderías AJ, Sánchez-Alonso I, Pérez-Mateos M. New applications of fibres in foods: addition to fishery products. Trends Food Sci Tech 2005; 16: 458-465.
7. Moreno H, Herranz B, Pérez-Mateos M, Isabel Sanchez-Alonso, Borderias AJ. New Alternatives in Seafood Restructured Products. Crit Rev Food Sci Nutr 2014. DOI: 10.1080/10408398.2012.719942.
8. Gonzalez-Canga A, Fernandez-Martinez N, Sahagun AM, Garcia- Vieitez JJ, Diez-Liebana MJ, Calle-Pardo AP, Castro-Robles LJ, Sierra-Vega M. Glucomanano: propiedades y aplicaciones terapeuticas. Nutr Hosp 2004; 19: 45-50.
9. Vázquez-Velasco M, González-Torres L, Olivero-David R, Bastida S, Benedí J, Sanchez-Reus M, González-Muñoz M, Sánchez-Muniz FJ. Lipoproteinemia and arylesterase activity in Zucker Fa/Fa rats fed glucomannan/spirulina-enriched squid-surimi. Eur J Lipid Sci Tech 2013; 115: 1274-1283.
10. Vázquez-Velasco M, González-Torres L, Lopez-Gasco P, Bastida S, Benedí J, Sanchez-Reus MI, González-Muñoz MJ, Sánchez-Muniz FJ. Liver oxidation and inflammation in Fa/ Fa rats fed glucomannan/spirulina-surimi. Food Chem 2014; 159: 215-221.
11. Vázquez-Velasco M, González-Torres L, Lopez-Gasco P, Bastida S, Benedí J, González-Muñoz MJ, Sánchez-Muniz FJ. Effects of glucomannan/spirulina-surimi on liver oxidation and inflammation in Zucker rats fed atherogenic diets. J Phys Biochem 2015. DOI 10.1007/s13105-015-0425-9
12. Vuksan V, Jenkins DJ, Spadafora P, Sievenpiper JL, Owen R, Vidgen E, Brighenti F, Josse R, Leiter LA, Bruce-Thompson C. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial. Diabetes Care 1999; 22: 913-919.
13. Nagaoka S, Shimizu K, Kaneko H, Shibayama F, Morikawa K, Kanamaru Y, Otsuka A, Hirahashi T, Kato T. A novel protein C-phycocyanin plays a crucial role in the hypocholesterolemic action of Spirulina platensis concentrate in rats. J Nutr 2005; 135: 2425-2430.
14. Joventino IP, Alves HG, Neves LC, Pinheiro-Joventino F, Leal LK, Neves SA, Ferreira FV, Brito GA, Viana GB. The microalga Spirulina platensis presents anti-inflammatory action as well as hypoglycemic and hypolipidemic properties in diabetic rats. J Complement Integr Med 2012; 9: 1553-3840.
15. Ou Y, Lin L, Yang X, Pan Q, Cheng X. Antidiabetic potential of phycocyanin: effects on KKAy mice. Pharm Biol 2013; 51: 539-544.
16. Fujimoto M, Tsuneyama K, Fujimoto T, Selmi C, Gershwin ME, Shimada Y. Spirulina improves non-alcoholic steatohepatitis, visceral fat macrophage aggregation, and serum leptin in a mouse model of metabolic syndrome. Dig Liver Dis 2012; 44: 767-774.
17. Lee EH, Park JE, Choi YJ, Huh KB, Kim WY. A randomized study to establish the effects of spirulina in type 2 diabetes mellitus patients. Nutr Res Pract 2008; 2: 295-300.
18. Campo-Deaño L, Tovar CA, Pombo MJ, Solas MT, Borderías AJ. Rheological study of giant squid surimi (Dosidicus gigas) made by two methods with different cryoprotectants added. J Food Eng 2009; 94: 26-33.
19. Borderías A, Perez Mateos M. Restructured fish products. Alimentaria (Espana) 1996. 269: 53-62.
20. Durham HA, Truett GE. Development of insulin resistance and hyperphagia in Zucker fatty rats. Am J Physiol Regul Integr Comp Physiol 2006; 290: R652-658.
21. Aleixandre de Artinano A, Miguel Castro M. Experimental rat models to study the metabolic syndrome. Br J Nutr 2009; 102: 1246-1253.
22. Guenther M, James R, Marks J, Zhao S, Szabo A, Kidambi S. Adiposity distribution influences circulating adiponectin levels. Transl Res 2014; 164: 270-277.
23. Lim S, Quon MJ, Koh KK. Modulation of adiponectin as a potential therapeutic strategy. Atherosclerosis 2014; 233: 721-728.
24. Paz-Filho G, Mastronardi CA, Licinio J. Leptin treatment: facts and expectations. Metabolism 2015; 64:146-156.
25. Sanchez-Muniz FJ. Dietary fibre and cardiovascular health. Nutr Hosp 2012; 27: 31-45.
26. Gesteiro E, Bastida S, Sanchez-Muniz FJ. Effects of maternal glucose tolerance, pregnancy diet quality and neonatal insulinemia upon insulin resistance/sensitivity biomarkers in normoweight neonates. Nutr Hosp 2011; 26: 1447-1455.
27. Gesteiro E, Bastida S, Sanchez-Muniz FJ. Insulin resistance markers in term, normoweight neonates. The Merida cohort. Eur J Pediatr 2009; 168: 281-288.
28. Parikh P, Mani U, Iyer U. Role of Spirulina in the Control of Glycemia and Lipidemia in Type 2 Diabetes Mellitus. J Med Food 2001; 4: 193-199.
29. Muthuraman P, Senthilkumar R, Srikumar K. Alterations in beta-islets of Langerhans in alloxan-induced diabetic rats by marine Spirulina platensis. J Enzyme Inhib Med Chem 2009; 24: 1253-1256.
30. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495.
31. Beaudoin MS, Snook LA, Arkell AM, Simpson JA, Holloway GP, Wright DC. Resveratrol supplementation improves white adipose tissue function in a depot-specific manner in Zucker diabetic fatty rats. Am J Physiol Regul Integr Comp Physiol 2013; 305: R542-551.
32. Candiracci M, Justo ML, Castano A, Rodriguez-Rodriguez R, Herrera MD. Rice bran enzymatic extract-supplemented diets modulate adipose tissue inflammation markers in Zucker rats. Nutrition 2014; 30: 466-472.
33. Martínez-Sesmero M. Riesgo cardiovascular en el estudio área de Toledo. Tesis Doctoral. Facultad de Farmacia. Universidad Complutense de Madrid. 2012.
34. Kim F, Pham M, Luttrell I, Bannerman DD, Tupper J, Thaler J, Hawn TR, Raines EW, Schwartz MW. Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet- induced obesity. Circ Res 2007; 100: 1589-1596.
35. Serrano-Ríos M, Gutiérrez-Fuentes JA. In Serrano-Ríos M, Ordovás JM, Gutiérrez-Fuentes JA, eds. Obesity. Chapter 13. Obesity and Type 2 Diabetes Mellitus. The reciprocal impact. Elsevier España; pp 215-232, Barcelona, 2011.
36. Panis C, Herrera AC, Aranome AM, Victorino VJ, Michelleti PL, Morimoto HK, Cecchini AL, Simao AN, Cecchini R. Clinical insights from adiponectin analysis in breast cancer patients reveal its anti-inflammatory properties in non-obese women. Mol Cell Endocrinol 2014; 382: 190-196.
37. Hardie LJ, Rayner DV, Holmes S, Trayhurn P. Circulating leptin levels are modulated by fasting, cold exposure and insulin administration in lean but not Zucker (fa/fa) rats as measured by ELISA. Biochem Biophys Res Commun 1996; 223: 660-665.
38. Considine RV, Caro JF. Leptin in humans: current progress and future directions. Clin Chem 1996; 42: 843-844.
39. Türkoğlu A, Böyük A, Tanrıverdi MH, Gündüz E, Dusak A, Kaplan İ, Gümüş M. The potential role of BMI, plasma leptin, nesfatin-1 and ghrelin levels in the early detection of pancreatic necrosis and severe acute pancreatitis: a prospective cohort study. Int J Surg 2014; 12:1310-1313.
40. Wędrychowicz A, Zając A, Pilecki M, Kościelniak B, Tomasik PJ. Peptides from adipose tissue in mental disorders. World J Psychiatry 2014; 4:103-111.
41. Fried SK, Ricci MR, Russell CD, Laferrere B. Regulation of leptin production in humans. J Nutr 2000; 130: 3127s-3131s.